Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
暂无分享,去创建一个
M. Pfisterer | F. Nietlispach | H. Brunner-La Rocca | H. Rickli | S. Muzzarelli | T. Burkard | S. Toggweiler | M. Maeder | B. Julius
[1] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[2] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[3] T. Fahey,et al. Spironolactone use and renal toxicity: population based longitudinal analysis , 2010, BMJ : British Medical Journal.
[4] M. Pfisterer,et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.
[5] A. Azevedo,et al. Safety of Spironolactone Use in Ambulatory Heart Failure Patients , 2008, Clinical cardiology.
[6] L. Ruilope,et al. Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) , 2008, Circulation.
[7] Akshay S. Desai,et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. , 2007, Journal of the American College of Cardiology.
[8] A. Ducharme,et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. , 2006, American heart journal.
[9] Tom Greene,et al. Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.
[10] M. Pfisterer,et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.
[11] S. Gottlieb,et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. , 2005, Journal of the American College of Cardiology.
[12] C. Gross,et al. Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001 , 2005, Circulation.
[13] J. Steward,et al. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. , 2005, Age and ageing.
[14] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[15] K. Tamirisa,et al. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. , 2004, American heart journal.
[16] A. Struthers,et al. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. , 2004, British journal of clinical pharmacology.
[17] B. Palmer. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.
[18] A. Laupacis,et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .
[19] D. Atar,et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? , 2004, Journal of cardiac failure.
[20] B. Pitt,et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.
[21] E. Mulkerrin,et al. Spironolactone therapy in older patients--the impact of renal dysfunction. , 2002, Archives of gerontology and geriatrics.
[22] K. Swedberg,et al. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.
[23] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[24] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[25] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[26] B. Pitt,et al. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .